StockData
NeOnc Technologies Holdings, Inc. logo

NeOnc Technologies Holdings, Inc. (NTHI) stock

NTHINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 0/30
$4.91+0.06 (+1.24%)

Close on Nov 13, 2026Market cap $127.35MP/E –Yield –

NeOnc Technologies Holdings, Inc. saw revenue fall 51.8% to $39.99K over fiscal 2025. Free cash flow was -$20.86M. At the latest close the market valued the company at $127.35M.

Revenue
$39.99K
-51.8% vs. a year earlier
Operating income
-$40.66M
TTM Q3 2026
Free cash flow
-$20.86M
FY2025
EPS, diluted
-$1.73
TTM Q3 2026

Key statistics

Valuation at the latest close; fundamentals over fiscal 2025, balances at Sep 30, 2026

Valuation

Market cap
$127.35M
P/E ratio
–
Price to sales
–
Price to book
–
Dividend yield
–
Free cash flow yield
–

Fundamentals

Revenue
$39.99K
Net income
-$43.02M
EPS, diluted
-$1.73
Free cash flow
-$20.86M
Book value per share
-$0.51
Diluted shares
26M

Trading

Next earnings
Apr 2, 2027 (estimated, after the close)
Previous close
$4.85
Open
$4.98
Day's range
$4.68 – $5.24
Volume
251,855
Average volume (20 days)
175,770
52-week range
$2.50 – $11.80
RSI (14 days)
78.3
Volatility (1 year)
112.7%
Relative volume
1.37×

On 2 of our idea lists: Insider cluster buys, Insiders buying the dip

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.

PeriodNTHIS&P 500DifferenceNTHI per yearS&P 500 per year
1 month+89.2%-3.0%+92.2 pts
3 months+53.0%-2.8%+55.7 pts
Year to date-40.6%+11.5%−52.1 pts
1 year-45.3%+13.5%−58.8 pts

Three years at a glance

Fiscal years 2023 to 2025 and trailing twelve months, USD

Revenue

–

Operating income

-$40.66M

Net income

-$43.02M

EPS, diluted

-$1.73

Free cash flow

–
Reported periodTrailing twelve months

Press releases

Releases NeOnc Technologies filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About NeOnc Technologies

Pharmaceutical Preparations

NeOnc Technologies is a clinical-stage biopharmaceutical company focused on developing therapies and novel delivery modalities for intracranial malignancies, including primary brain tumors such as glioblastoma and meningioma, as well as secondary brain metastases. The company's pipeline centers on two investigational candidates: NEO100, a purified perillyl alcohol administered intranasally to bypass the blood-brain barrier, and NEO212, an oral and intranasal conjugate of temozolomide and perillyl alcohol. NeOnc currently conducts human clinical trials across targeted patient populations lacking effective alternatives, while also exploring delivery applications for neurodegenerative conditions.

Company profile, executives and history

NeOnc Technologies stock: common questions

What is NeOnc Technologies's stock price?

NTHI closed at $4.91 on Nov 13, 2026, up 1.24% on the day. Over the past 52 weeks it traded between $2.50 and $11.80.

What is NeOnc Technologies's market cap?

NeOnc Technologies was worth $127.35M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.

What is NTHI's P/E ratio?

NeOnc Technologies lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.73), so it has no meaningful P/E ratio.

How much revenue does NeOnc Technologies make?

NeOnc Technologies reported revenue of $39.99K for fiscal 2025, down 51.8% from a year earlier.

Does NeOnc Technologies pay a dividend?

No. NeOnc Technologies has not paid a cash dividend over the last twelve months.

When does NeOnc Technologies report earnings next?

NeOnc Technologies is expected to report Q4 FY2026 results on Apr 2, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.

How has NTHI stock performed over the past year?

Including dividends, NTHI returned -45.3% over the past year, against +13.5% for the S&P 500.

How many NTHI shares are sold short?

1M shares were sold short at the latest FINRA report, 8.89% of the float, or 7.0 days of average trading volume.

Who are NeOnc Technologies's competitors?

Companies most similar to NeOnc Technologies by business, industry and size include KZIA, CNBX, ALT, IXHL, IBO.

See a number that looks wrong?